Recurrent gene fusions in prostate cancer
First Claim
Patent Images
1. A composition comprising an antibody that is specific for a truncated ERG1 protein, wherein the truncated ERG1 protein has an amino acid sequence that begins at a methionine that is the 47th amino acid of SEQ ID NO:
- 240 and the antibody binds an epitope comprising the 47th amino acid of SEQ ID NO;
240.
4 Assignments
0 Petitions
Accused Products
Abstract
Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.
-
Citations
11 Claims
-
1. A composition comprising an antibody that is specific for a truncated ERG1 protein, wherein the truncated ERG1 protein has an amino acid sequence that begins at a methionine that is the 47th amino acid of SEQ ID NO:
- 240 and the antibody binds an epitope comprising the 47th amino acid of SEQ ID NO;
240. - View Dependent Claims (2, 3, 4, 5)
- 240 and the antibody binds an epitope comprising the 47th amino acid of SEQ ID NO;
- 6. A composition comprising an antibody that binds an epitope comprising the 47th amino acid of SEQ ID NO:
-
8. A composition comprising an antibody that binds an epitope comprising the 47th amino acid of SEQ ID NO:
- 240 that is a truncated ERG1 protein encoded by a gene fusion resulting from rearrangement of TMPRSS2 and ERG1 genes.
- View Dependent Claims (9, 10, 11)
Specification